Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Value of routine 'day 14' marrow exam in newly diagnosed AML.
Yezefski T, Xie H, Walter R, Pagel J, Becker PS, Hendrie P, Sandhu V, Shannon-Dorcy K, Abkowitz J, Appelbaum FR, Estey E. Yezefski T, et al. Among authors: becker ps. Leukemia. 2015 Jan;29(1):247-9. doi: 10.1038/leu.2014.268. Epub 2014 Sep 10. Leukemia. 2015. PMID: 25204570 No abstract available.
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival MM, Estey EH, Stirewalt DL, Walter RB. Halpern AB, et al. Among authors: becker ps. Leukemia. 2017 Dec;31(12):2560-2567. doi: 10.1038/leu.2017.165. Epub 2017 May 30. Leukemia. 2017. PMID: 28555084 Free PMC article. Clinical Trial.
The proportion of CD34(+)CD38(low or neg) myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia.
Roshal M, Chien S, Othus M, Wood BL, Fang M, Appelbaum FR, Estey EH, Papayannopoulou T, Becker PS. Roshal M, et al. Among authors: becker ps. Leukemia. 2013 Mar;27(3):728-31. doi: 10.1038/leu.2012.217. Epub 2012 Jul 31. Leukemia. 2013. PMID: 22926686 Free PMC article. No abstract available.
A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.
Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley SD, Kim DD, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S, Mineishi S. Magenau J, et al. Among authors: becker ps. Bone Marrow Transplant. 2017 Jan;52(1):59-65. doi: 10.1038/bmt.2016.188. Epub 2016 Jul 18. Bone Marrow Transplant. 2017. PMID: 27427921 Free PMC article. Clinical Trial.
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH, Mazumder A, Crowley J, Becker P, Hilger J, Durie BG. Bensinger WI, et al. Br J Haematol. 2010 Feb;148(4):562-8. doi: 10.1111/j.1365-2141.2009.07981.x. Epub 2009 Nov 16. Br J Haematol. 2010. PMID: 19919652 Free article. Clinical Trial.
190 results